Localized Prostate Cancer

The standard set

The ICHOM Standard Set for Localized Prostate Cancer is the result of hard work by a group of leading physicians, measurement experts and patients. It is our recommendation of the outcomes that matter most to patients with Localized Prostate Cancer. We urge all providers around the world to start measuring these outcomes to better understand how to improve the lives of their patients.

1 Recorded via the Clavien-Dindo-Classification

2 Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0

3 Recommend to track via the Expanded Prostate Cancer Index Composite (EPIC)-26

Implement with ICHOM

View testimonials from our Working Group members

Our Working Group members voluntarily spent 8-12 months developing this Set. Hear their personal motivations

This will transform care delivery in localized prostate cancer. Hear why

The Sets are developed on a foundation of experience and expertise. Hear more about the people and the process

Listen to how you could get involved...

STANDARD SET MATERIALS

Standard Set materials have moved to ICHOM Connect and are still available free of charge. Please log in or register to gain access to unlimited ICHOM resources at a single click of a button. There, you can also indicate your interest in receiving updates about and implementing the Standard Set.

Available materials:

Flyer – a brief overview of the most important outcomes for patients relating to this ICHOM Standard Set.
Reference Guide – a complete overview of the ICHOM Standard Set, including definitions for each measure and selected PROM instruments, time points for collection, and associated risk factors.
Data Dictionary – an index of the outcomes and case-mix variables included in the standard set, how to code them, and the information you need to collect when implementing the outcomes in practice.
Press Release
Published Articles
Additional materials

ICHOM Connect

Team that developed this standard

Australia

Kim Moretti | South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC); The Queen Elizabeth Hospital
Mark Frydenberg | Prostate Cancer Registry of Victoria; Monash University. South Australien Prostate Cancer Clinical Outcomes
Ian Roos* | Melbourne Graduate School of Education, University of Melbourne; Cancer Action Victoria

Germany

Hartwig Huland | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Markus Graefen | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Michael Froehner | University Hospital Carl Gustav Carus, Technical University of Dresden
Thomas Wiegel | University Hospital Ulm
Günter Feick* | Bundesverband Prostatakrebs Selbsthilfe (BPS); Europa UOMO

Ireland

Frank Sullivan | Galway University Hospital; Prostate Cancer Institute at NUI Galway
John Fitzpatrick | Irish Cancer Society

Israel

Jacob Ramon | Sheba Medical Center

Italy

Alberto Briganti | Vita-Salute San Raffaele University Hospital

Netherlands

Chris Bangma | Erasmus Medical Center

Sweden

Anna Bill-Axelson | Uppsala University Hospital; National Prostate Cancer Register (NPCR) of Sweden

United Kingdom

Adam Glaser | Leeds Teaching Hospitals NHS Trust
James Catto | Academic Urology Unit and Academic Unit of Molecular Oncology, CR-UK/YCR Sheffield Cancer Research Centre

United States

Steven Jay Frank | MD Anderson Cancer Center
David Swanson | MD Anderson Cancer Center
Andrew Vickers | Memorial Sloan-Kettering Cancer Center
Adam Kibel | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Anthony D’Amico | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Neil Martin | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Michael Blute | Massachusetts General Hospital
Howard Sandler | Cedars-Sinai Medical Center
Ronald Chen | University of North Carolina Lineberger Comprehensive Cancer Center
Nancy Mendenhall | University of Florida Proton Therapy Institute
Daniel Hamstra | University of Michigan Health System
Ashutosh Tewari | Icahn School of Medicine at Mount Sinai Hospital

*Patient representative

Stay up to date

To receive updates about this standard set, including new versions, please click on the box below.

Receive Updates

View more standard sets

1
2
3
4

Localized Prostate Cancer

The standard set

View testimonials from our Working Group members

STANDARD SET MATERIALS